http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2015111627-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2012-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2015111627-A |
| titleOfInvention | Cancer Screening Methods |
| abstract | 1. Method III cancer screening, comprising detecting the methylation status of the target gene in the cells of the sample as a screening indicator of the presence or absence of cancer, characterized in that it includes first providing a sample for detection, then detecting the methylation status of the CpG sequence, at least , in one target gene, which are ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in the genomic DNA of the sample, and then determine the presence of cancer or pre-tumor changes in the sample usu methylation of the target gene or use of methylation status as a prognostic indicator after lecheniya.2. The method of claim 1, wherein the detection sample is a Pap smear, ascitic fluid, blood, urine, feces, sputum, oral mucosa cells, gastric juice, bile, cervical epithelial cells, or an in vitro tumor tissue sample after surgery. 3. The method according to claim 1, characterized in that the methylation status of the target gene CpG is detected in a methylation-specific polymerase chain reaction specific for methylation of a quantitative polymerase chain reaction, bisulfite sequencing, microarray analysis, mass spectrometry, denaturing high-performance liquid chromatography or pyrosequencing .four. The method according to claim 1, characterized in that the target ADRA1D gene has a nucleotide sequence according to SEQ ID NO: 1; the target AJAP1 gene has a nucleotide sequence according to SEQ ID NO: 2; the target HS3ST2 gene has a nucleotide sequence according to SEQ ID NO: 3; the target MAGI2 gene has a nucleotide sequence according to SEQ ID NO: 4; target gene POU4F2 |
| priorityDate | 2012-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.